Attract talent


1 Follower


Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and ...


Add photos to showcase Volastra’s culture


Add Volastra’s values

Insider experiences

Share your experience of working at Volastra

Charles Hugh-Jones
Chief Executive Officer
Michael Su
Chief Scientific Officer
Diane Tager
VP, Business Dev & Operations
Rumin Zhang
VP, Biochemistry
Derek Cogan
Senior Director, Chemistry
Christina Eng
Director, Biology
Yazen Jmeian
Director, Bio-therapeutics
Sarah Bettigole
Senior Scientist, Immunology
Hyeseok Shim
Senior Scientist, Biology
Michael Arensman
Senior Scientist, Biology

Add your teams to show how people work together at Volastra

Add jobs to your org chart to show candidates who they’ll work with

Publish company announcements to get more exposure

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.